SCHEMBL4764732

SCHEMBL4764732

OCc1cc2c(Nc3cccc(Cl)c3)ncnc2[nH]1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTBK1 Q5TCY1 1/20 0.60
TTBK2 Q6IQ55 1/20 0.60
EGFR P00533 11/20 0.56
ABL1 P00519 2/20 0.56
ABL2 P42684 2/20 0.56
FADS1 O60427 2/20 0.55
ERBB2 P04626 2/20 0.55
LCK P06239 1/20 0.54
NUDT1 P36639 1/20 0.53
PDGFRB P09619 1/20 0.53
KDM4E B2RXH2 1/20 0.52
MEN1 O00255 1/20 0.52
NPC1 O15118 1/20 0.52
PRNP P04156 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2D6 P10635 1/20 0.52
MAPT P10636 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7498310 0.89 TTBK1 (0.61) TTBK1TTBK2EGFRABL1ABL2
SCHEMBL7498340 0.88 TTBK1 (0.60) TTBK1TTBK2EGFRABL1ABL2
SCHEMBL27444973 0.85 PDGFRB (0.59) TTBK1TTBK2EGFRABL1ABL2
SCHEMBL7881668 0.85 TTBK1 (0.52) TTBK1TTBK2EGFRABL1ABL2
SCHEMBL7498456 0.84 TTBK1 (0.56) TTBK1TTBK2EGFRABL1ABL2
SCHEMBL7495114 0.84 TTBK1 (0.56) TTBK1TTBK2EGFRABL1ABL2
SCHEMBL4361412 0.81 EGFR (0.60) TTBK1TTBK2EGFRABL1ABL2
SCHEMBL7496462 0.80 TTBK1 (0.51) TTBK1TTBK2EGFRABL1ABL2
SCHEMBL7881664 0.79 TTBK1 (0.53) TTBK1TTBK2EGFRABL1ABL2
SCHEMBL4767556 0.79 EGFR (0.51) TTBK1TTBK2EGFRABL1ABL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1100778-C Pyrrolopyrimidines and process for their preparation NOVARTIS CO (CH) 2003-02-05 CN claimed
EP-0836605-B1 PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF NOVARTIS AG (CH) 2002-02-06 EP claimed
CN-1194647-A Pyrrolopyrimidines and processes for preparation thereof NOVARTIS CO (CH) 1998-09-30 CN claimed
EP-0836605-A1 PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF Novartis AG (CH) 1998-04-22 EP claimed
WO-1997002266-A1 PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF NOVARTIS AG (CH) 1997-01-23 WO claimed
EP-0938486-B1 SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION NOVARTIS AG (CH) 2008-01-16 EP disclosed
CN-1100778-C Pyrrolopyrimidines and process for their preparation NOVARTIS CO (CH) 2003-02-05 CN disclosed
EP-0836605-B1 PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF NOVARTIS AG (CH) 2002-02-06 EP disclosed
US-6180636-B1 USED TO INHIBIT THE TYROSINE KINASE ACTIVITY OF THE RECEPTOR FOR THE EPIDERMAL GROWTH FACTOR AND C-ERBB2 KINASE AND CAN BE USED AS ANTITUMOR AGENTS NOVARTIS AG (CH) 2001-01-30 US disclosed
US-6140332-A Pyrrolopyrimidines and processes for the preparation thereof NOVARTIS AG (CH) 2000-10-31 US disclosed
EP-0938486-A1 SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION Novartis AG (CH) 1999-09-01 EP disclosed
CN-1194647-A Pyrrolopyrimidines and processes for preparation thereof NOVARTIS CO (CH) 1998-09-30 CN disclosed
EP-0836605-A1 PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF Novartis AG (CH) 1998-04-22 EP disclosed
WO-1998007726-A1 SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION NOVARTIS AG (CH) 1998-02-26 WO disclosed
WO-1997002266-A1 PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF NOVARTIS AG (CH) 1997-01-23 WO disclosed